News - Biosimilars, AbbVie

Filter

Current filters:

BiosimilarsAbbVie

Popular Filters

1 to 25 of 116 results

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

14-04-2014

US drugmaker AbbVie has revealed promising new results from its hepatitis C development program at the…

AbbVieAnti-viralsPharmaceuticalResearchUSA

EGA president seeks partnership with Italian government on generics and biosimilars

09-04-2014

The president of the European Generic Medicines Association (EGA), Nick Haggar, attended the Stati Generali…

BiosimilarsEuropeGenericsItalyMarkets & MarketingPolitics

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

07-04-2014

Uptake of biosimilars in Europe has increased as a result of member states’ policies, according to…

BiosimilarsEuropeFilgrastimInterviewsMarkets & MarketingRegulationSandoz

EGA Biosimilars: European monitoring and global business opportunities

EGA Biosimilars: European monitoring and global business opportunities

07-04-2014

The spotlight was on the European uptake of biosimilars at the European Generic medicines Association’s…

BiosimilarsEuropeGlobalInterviewsMarkets & Marketing

EGA Biosimilars: Call for regulatory authorities to improve awareness of biosimilars

EGA Biosimilars: Call for regulatory authorities to improve awareness of biosimilars

04-04-2014

Clear and unbiased information on biosimilars is needed to increase uptake of the medicines across Europe,…

BiosimilarsEurope

EMA confirms AbbVie’s withdrawal of court cases on access to clinical-trial data

04-04-2014

The European Medicines Agency confirms that US drugmaker AbbVie has withdrawn both its court cases brought…

AbbVieEuropeLegalPharmaceuticalResearch

Fast growth forecast for South Korean pharma market

Fast growth forecast for South Korean pharma market

02-04-2014

South Korea's pharmaceuticals market was valued at $20 billion in 2012, growing from $14.5 billion in…

Asia-PacificBiosimilarsBiotechnologyMarkets & MarketingPricingResearch

Lupin launches generic Niaspan in USA

24-03-2014

Indian drugmaker Lupin says that its US subsidiary has launched its niacin extended-release tablets USP,…

AbbVieCardio-vascularGenericsLupinMarkets & MarketingNiaspanNorth AmericaUSA

Global microvascular complications of diabetes market value to almost double by 2022

Global microvascular complications of diabetes market value to almost double by 2022

20-03-2014

The microvascular complications of diabetes pharmaceutical market value in the seven major countries…

AbbVieatrasentanDiabetesGlobalMarkets & MarketingPharmaceutical

Pan-European survey calls for a shift in policy for biosimilars

Pan-European survey calls for a shift in policy for biosimilars

19-03-2014

This week, the Alliance for Safe Biologic Medicines (ASBM) disclosed the results of a survey of 470 European…

BiosimilarsBiotechnologyEuropeHealthcareRegulation

EGA calls for removal of barriers to competition and free trade for generics

EGA calls for removal of barriers to competition and free trade for generics

19-03-2014

The European Union must remove barriers to competition and free trade by introducing common sense reforms…

BiosimilarsEuropeGenericsMarkets & MarketingPatentsRegulation

AbbVie presents positive Phase III results in patients with chronic hepatitis C

AbbVie presents positive Phase III results in patients with chronic hepatitis C

04-03-2014

The first detailed results from US drugmaker AbbVie’s pivotal Phase III study, PEARL-III, have been…

AbbVieAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

India now making moves into pharma innovation

India now making moves into pharma innovation

03-03-2014

In what must be seen as a significant change in focus, India is now seeing a surge of innovative research…

Asia-PacificBiosimilarsIndiaMarkets & MarketingPharmaceuticalResearch

BIO urges Indiana Governor to sign Bill on interchangeable biologic medicines

27-02-2014

US trade group the Biotechnology Industry Organization (BIO) and the Indiana Health Industry Forum (IHIF)…

BiosimilarsGenericsLegalNorth AmericaRegulationUSA

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

26-02-2014

The local subsidiary of Israeli generics giant Teva Pharmaceutical Industries has launched Lonquex (lipegfilgrastim)…

AmgenBiosimilarsGenericsLonquexMarkets & MarketingNorthern EuropeOncologyTeva Pharmaceutical IndustriesUK

Merck names Simon Sturge as new head of biosimilars unit

Merck names Simon Sturge as new head of biosimilars unit

20-02-2014

Germany’s Merck KGaA has appointed Simon Sturge to head the biosimilars unit, effective March 1, succeeding…

BiosimilarsBiotechnologyBoardroomManagementMerck KGaA

Viiv Healthcare comes out top in global survey of pharma industry reputations

14-02-2014

An independent global study has recorded the latest impressions of the corporate reputation of the world’s…

AbbVieGlobalPharmaceuticalResearchViiV Healthcare

Kissei collaborates with Alteogen on biosimilars

14-02-2014

Japanese drugmaker Kissei Pharmaceutical has entered into a business collaboration agreement with South…

BiosimilarsBiotechnologyKissei PharmaceuticalResearch

Cadila net profit up by 82% in third-quarter

07-02-2014

Indian drugmaker Cadila Healthcare posted a net profit of 1.86 billion rupees ($29.7 million), for the…

BiosimilarsCadila PharmaceuticalsFinancialGenericsResearchZydus Cadila

1 to 25 of 116 results

Back to top